Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas

Timothy Kottke, Jose S Pulido, Jill Thompson, Luis Sanchez-Perez, Heung Chong, Stuart K. Calderwood, Peter Selby, Kevin Harrington, Scott E. Strome, Alan Melcher, Richard Geoffrey Vile

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We have a long-term interest in the connectivity between autoimmunity and tumor rejection. However, outside of the melanocyte/melanoma paradigm, little is known about whether autoimmune responses to normal tissue can induce rejection of tumors of the same histologic type. Here, we induced direct, pathogen-like cytotoxicity to the normal pancreas in association with the immune adjuvant heat shock protein 70. In sharp contrast to our studies with a similar approach for the treatment of prostate cancer, inflammatory killing of the normal pancreas induced a Th1-like, anti-self-response to pancreatic antigens, which was rapidly suppressed by a concomitant suppressive regulatory T cell (Treg) response. Interestingly, even when Treg cells were depleted, the Th1-like response was insufficient to induce significant ongoing autoimmunity. However, the Th1-like response to antigens expressed in the pancreas at the time of damage was sufficient to induce rejection of tumors expressing either a foreign (ova) antigen or fully syngeneic tumor antigens (on Panc02 tumor cells), provided that Treg were depleted before inflammatory killing of the normal pancreas. Taken together, these data indicate that profound differences exist between the immunoprotective mechanisms in place between different tissues (pancreas and prostate) in their response to pathogen-like damage. Moreover, they also show that, although multiple layers of immunologic safeguards are in place to prevent the development of severe autoimmune consequences in the pancreas (in contrast to the prostate), tumor rejection responses can still be decoupled from pathologic autoimmune responses in vivo, which may provide novel insights into the immunotherapeutic treatment of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)7767-7774
Number of pages8
JournalCancer Research
Volume69
Issue number19
DOIs
StatePublished - Oct 1 2009

Fingerprint

HSP70 Heat-Shock Proteins
Autoimmunity
Pancreas
Immunity
Regulatory T-Lymphocytes
Neoplasms
Antigens
Prostate
Melanocytes
Neoplasm Antigens
Pancreatic Neoplasms
Ovum
Melanoma
Prostatic Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. / Kottke, Timothy; Pulido, Jose S; Thompson, Jill; Sanchez-Perez, Luis; Chong, Heung; Calderwood, Stuart K.; Selby, Peter; Harrington, Kevin; Strome, Scott E.; Melcher, Alan; Vile, Richard Geoffrey.

In: Cancer Research, Vol. 69, No. 19, 01.10.2009, p. 7767-7774.

Research output: Contribution to journalArticle

Kottke, T, Pulido, JS, Thompson, J, Sanchez-Perez, L, Chong, H, Calderwood, SK, Selby, P, Harrington, K, Strome, SE, Melcher, A & Vile, RG 2009, 'Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas', Cancer Research, vol. 69, no. 19, pp. 7767-7774. https://doi.org/10.1158/0008-5472.CAN-09-1597
Kottke, Timothy ; Pulido, Jose S ; Thompson, Jill ; Sanchez-Perez, Luis ; Chong, Heung ; Calderwood, Stuart K. ; Selby, Peter ; Harrington, Kevin ; Strome, Scott E. ; Melcher, Alan ; Vile, Richard Geoffrey. / Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. In: Cancer Research. 2009 ; Vol. 69, No. 19. pp. 7767-7774.
@article{9661dd9521b24b28ab011715b46026a3,
title = "Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas",
abstract = "We have a long-term interest in the connectivity between autoimmunity and tumor rejection. However, outside of the melanocyte/melanoma paradigm, little is known about whether autoimmune responses to normal tissue can induce rejection of tumors of the same histologic type. Here, we induced direct, pathogen-like cytotoxicity to the normal pancreas in association with the immune adjuvant heat shock protein 70. In sharp contrast to our studies with a similar approach for the treatment of prostate cancer, inflammatory killing of the normal pancreas induced a Th1-like, anti-self-response to pancreatic antigens, which was rapidly suppressed by a concomitant suppressive regulatory T cell (Treg) response. Interestingly, even when Treg cells were depleted, the Th1-like response was insufficient to induce significant ongoing autoimmunity. However, the Th1-like response to antigens expressed in the pancreas at the time of damage was sufficient to induce rejection of tumors expressing either a foreign (ova) antigen or fully syngeneic tumor antigens (on Panc02 tumor cells), provided that Treg were depleted before inflammatory killing of the normal pancreas. Taken together, these data indicate that profound differences exist between the immunoprotective mechanisms in place between different tissues (pancreas and prostate) in their response to pathogen-like damage. Moreover, they also show that, although multiple layers of immunologic safeguards are in place to prevent the development of severe autoimmune consequences in the pancreas (in contrast to the prostate), tumor rejection responses can still be decoupled from pathologic autoimmune responses in vivo, which may provide novel insights into the immunotherapeutic treatment of pancreatic cancer.",
author = "Timothy Kottke and Pulido, {Jose S} and Jill Thompson and Luis Sanchez-Perez and Heung Chong and Calderwood, {Stuart K.} and Peter Selby and Kevin Harrington and Strome, {Scott E.} and Alan Melcher and Vile, {Richard Geoffrey}",
year = "2009",
month = "10",
day = "1",
doi = "10.1158/0008-5472.CAN-09-1597",
language = "English (US)",
volume = "69",
pages = "7767--7774",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas

AU - Kottke, Timothy

AU - Pulido, Jose S

AU - Thompson, Jill

AU - Sanchez-Perez, Luis

AU - Chong, Heung

AU - Calderwood, Stuart K.

AU - Selby, Peter

AU - Harrington, Kevin

AU - Strome, Scott E.

AU - Melcher, Alan

AU - Vile, Richard Geoffrey

PY - 2009/10/1

Y1 - 2009/10/1

N2 - We have a long-term interest in the connectivity between autoimmunity and tumor rejection. However, outside of the melanocyte/melanoma paradigm, little is known about whether autoimmune responses to normal tissue can induce rejection of tumors of the same histologic type. Here, we induced direct, pathogen-like cytotoxicity to the normal pancreas in association with the immune adjuvant heat shock protein 70. In sharp contrast to our studies with a similar approach for the treatment of prostate cancer, inflammatory killing of the normal pancreas induced a Th1-like, anti-self-response to pancreatic antigens, which was rapidly suppressed by a concomitant suppressive regulatory T cell (Treg) response. Interestingly, even when Treg cells were depleted, the Th1-like response was insufficient to induce significant ongoing autoimmunity. However, the Th1-like response to antigens expressed in the pancreas at the time of damage was sufficient to induce rejection of tumors expressing either a foreign (ova) antigen or fully syngeneic tumor antigens (on Panc02 tumor cells), provided that Treg were depleted before inflammatory killing of the normal pancreas. Taken together, these data indicate that profound differences exist between the immunoprotective mechanisms in place between different tissues (pancreas and prostate) in their response to pathogen-like damage. Moreover, they also show that, although multiple layers of immunologic safeguards are in place to prevent the development of severe autoimmune consequences in the pancreas (in contrast to the prostate), tumor rejection responses can still be decoupled from pathologic autoimmune responses in vivo, which may provide novel insights into the immunotherapeutic treatment of pancreatic cancer.

AB - We have a long-term interest in the connectivity between autoimmunity and tumor rejection. However, outside of the melanocyte/melanoma paradigm, little is known about whether autoimmune responses to normal tissue can induce rejection of tumors of the same histologic type. Here, we induced direct, pathogen-like cytotoxicity to the normal pancreas in association with the immune adjuvant heat shock protein 70. In sharp contrast to our studies with a similar approach for the treatment of prostate cancer, inflammatory killing of the normal pancreas induced a Th1-like, anti-self-response to pancreatic antigens, which was rapidly suppressed by a concomitant suppressive regulatory T cell (Treg) response. Interestingly, even when Treg cells were depleted, the Th1-like response was insufficient to induce significant ongoing autoimmunity. However, the Th1-like response to antigens expressed in the pancreas at the time of damage was sufficient to induce rejection of tumors expressing either a foreign (ova) antigen or fully syngeneic tumor antigens (on Panc02 tumor cells), provided that Treg were depleted before inflammatory killing of the normal pancreas. Taken together, these data indicate that profound differences exist between the immunoprotective mechanisms in place between different tissues (pancreas and prostate) in their response to pathogen-like damage. Moreover, they also show that, although multiple layers of immunologic safeguards are in place to prevent the development of severe autoimmune consequences in the pancreas (in contrast to the prostate), tumor rejection responses can still be decoupled from pathologic autoimmune responses in vivo, which may provide novel insights into the immunotherapeutic treatment of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=70350218802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350218802&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-1597

DO - 10.1158/0008-5472.CAN-09-1597

M3 - Article

C2 - 19738045

AN - SCOPUS:70350218802

VL - 69

SP - 7767

EP - 7774

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 19

ER -